Table 3.
Nonadherence to Prescribed Medications (Percentage of Days Nonadherent During the 12-Month Prerandomization and Postrandomization Periods)
| Medication | Usual Care % of Days Mean (SD)* [No. of Patients] | Intervention % of Days Mean (SD)* [No. of Patients] | Adjusted Mean Difference % of Days (95% CI)† |
| Oral hypoglycemic agent | |||
| Prerandomization | 22.9 (24.0) [103] | 19.8 (21.3) [103] | |
| Postrandomization‡ | 24.0 (24.7) [103] | 28.2 (28.9) [103] | –6.3 (–11.91 to −0.71) |
| ACE inhibitor | |||
| Prerandomization | 29.7 (29.3) [65] | 27.4 (27.1) [54] | |
| Postrandomization | 18.9 (17.4) [52] | 24.2 (22.7) [59] | –2.5 (–8.69 to 3.70) |
| Lipid-lowering agent | |||
| Prerandomization | 24.5 (23.0) [52] | 29.3 (26.7) [50] | |
| Postrandomization | 27.7 (24.0) [63] | 28.8 (27.1) [54] | –0.2 (–7.23 to 6.76) |
CI = confidence interval; ACE = angiotensin-converting enzyme.
* Means and SDs are unadjusted.
† Estimated differences and 95% CIs are based on regression models that adjusted for the baseline value, age, sex, race, education, comorbid conditions other than diabetes and depression, complications, and use of insulin, with variance estimates that account for clustering of measurements within patients, patients within physicians, and physicians within clinics.
‡ Intervention and usual care groups differ significantly, P <.03.